Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
|Videos|November 4, 2021
Emerging Psychedelic Therapies
Author(s)Alexander Somjen
Here's why psychedelics might be a valuable addition to mental health treatment.
Advertisement
Alexander Somjen discusses the fragmented psychedelic industry, regulatory frameworks, and potential commercial success.
Alexander Somjen is the CEO and Director of
Advertisement
Related to this article
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Psychedelic psilocybin therapy shows year-long relief in treatment-resistant depression, with strong response rates and stable safety.
FDA boosts DT120 lysergide ODT after phase 3 shows lasting depression relief; psychedelic tablet also advances for anxiety and other brain disorders.
New trial shows edible THC worsens lane control and reaction time at low blood levels, raising doubts about current legal impairment limits.
International Overdose Awareness Day marks 25 years, spotlighting fragile declines in deaths and urging naloxone access, harm reduction funding, and stigma-free care.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Vol 43, Issue 9 - Interactive
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
Insights on the New Adult ADHD Guidelines: A Conversation With the President of APSARD
4
New Adult ADHD Guidelines: What Resources Are Coming Soon
5